Vitamin C Slows Bone Marrow Aging by 4 Years in Primates
Long-term oral vitamin C supplementation reversed key markers of bone marrow aging in primates, cutting transcriptomic age by ~4 years.
Summary
As we age, our bone marrow produces fewer immune cells and shifts toward inflammatory myeloid output — a process thought to be largely irreversible. This primate study challenges that assumption. Researchers mapped the single-cell gene activity of aging bone marrow in primates and then tested whether long-term oral vitamin C supplementation could reverse the decline. It did — at least partially. Vitamin C expanded the pool of common lymphoid progenitors (the cells that give rise to immune cells), rebalanced blood cell production away from the myeloid-biased aging pattern, and was associated with a roughly four-year reduction in transcriptomic age estimates, cross-validated by an epigenetic clock. The study also identified progranulin signaling as a potential molecular pathway behind these effects, with human cell experiments supporting that connection.
Detailed Summary
Bone marrow aging is one of the least-discussed but most consequential aspects of growing old. As the marrow ages, production of immune cells declines, inflammatory myeloid cells dominate, and the body's ability to fight infection and repair itself diminishes. Whether this process can be meaningfully slowed — especially in primates, whose biology closely mirrors humans — has remained an open question.
This study from the Chinese Academy of Sciences, published in Cell Stem Cell, addressed that question directly. The researchers used single-cell RNA sequencing to map the transcriptomic landscape of primate bone marrow at different ages, generating a high-resolution picture of how gene activity changes across individual cell types during aging. They then administered long-term oral vitamin C supplementation to aged primates and re-examined the marrow.
The results were striking. Aging was associated with severe depletion of common lymphoid progenitors (CLPs) — the upstream cells that generate T cells, B cells, and NK cells — along with a myeloid-biased shift in hematopoietic stem and progenitor cell output. Vitamin C partially reversed both phenomena: it expanded the CLP pool and rebalanced lineage commitment trajectories. Transcriptomic age estimates were reduced by approximately four years, a finding cross-validated by an epigenetic clock, lending strong credibility to the functional magnitude of the effect.
Mechanistically, cell-cell communication analyses pointed to progranulin (GRN) signaling as a key vitamin C-responsive pathway. Human in vitro experiments showed that recombinant progranulin could replicate selected molecular actions of vitamin C, nominating it as a candidate mediator worth pursuing in future work.
Caveats are important: the study was conducted in non-human primates, and the optimal dosing, duration, and translational relevance for humans remain to be established. The summary is based on the abstract only, so specific sample sizes, doses, and full statistical details are not available. Nevertheless, this research positions vitamin C — an inexpensive, widely available supplement — as a biologically plausible intervention against hematopoietic aging.
Key Findings
- Long-term oral vitamin C reduced transcriptomic bone marrow age by ~4 years in primates, confirmed by epigenetic clock.
- Vitamin C expanded the common lymphoid progenitor pool, partially reversing age-related immune cell depletion.
- Supplementation rebalanced hematopoietic stem cell output away from the inflammatory myeloid-biased aging pattern.
- Progranulin (GRN) signaling was identified as a key vitamin C-responsive pathway in bone marrow.
- Human in vitro assays showed recombinant progranulin mimics selected vitamin C molecular actions.
Methodology
The study used single-cell RNA sequencing to map primate bone marrow aging at transcriptomic resolution across cell types. Long-term oral vitamin C was administered to aged primates, with pre/post comparisons of progenitor populations, lineage trajectories, and transcriptomic age clocks. Cell-cell communication analyses and human in vitro progranulin assays complemented the in vivo primate data.
Study Limitations
The study was conducted in non-human primates; direct translation to human bone marrow aging requires validation in human clinical trials. This summary is based on the abstract only — specific dosing regimens, sample sizes, and full statistical analyses are not available. The progranulin pathway findings are preliminary and require further mechanistic validation in vivo.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: